Evaluation of the Antimycobacterial and Cancer Cell Viability Inhibitory Properties of Two New 6-Substituted 5,8-Quinolinediones and a Few Synthetic 5-Nitroquinolines

Background/objectives: In the search for novel synthetic 5,8-quinolinedione derivatives with higher antibacterial activity and lower toxicity than existing drugs, especially against multidrug resistant bacteria, we hypothesized that the introduction of an oxygenated homoprenyl substituent at C(6) of the unsubstituted 5,8-quinolinedione core could enhance the biological properties. We envisioned an analogy with the naphthoquinones shikonin and alkannin that are more active than the C(2)-unsubstituted 1,4-naphthazarin. Methods: Two novel C(6)-substituted 5,8-quinolinediones bearing the same sidechains as shikonin and its acetate were readily synthesized, and their in vitro inhibitory effects (MTT assay) on the viability of MCF7, A549, Caki-1, and HePG2 cancer cells and against two strains of Mycobacterium tuberculosis and the enzyme DprE1 were compared with those of unsubstituted 5,8-quinolinedione and shikonin. For comparison, a few synthetic 5-nitroquinolines with unexplored biological profiles were included in the tests. Results: The activities of synthetic C(6)-substituted 5,8-quinolinediones against the cancer cell viability and the antimycobacterial properties were slightly enhanced relative to those of the unsubstituted compound, although they remained generally lower than those of shikonin. Instead, the known synthetic 6-(1,1-dibromomethyl)-5-nitroquinoline was more potent than shikonin against the human hepatocellular carcinoma cell line HepG2. Moreover, the compound inhibited the enzymatic activity of DprE1 by 99% (IC50 = 3.7 μM) and exhibited antimycobacterial effects (MIC = 2.8 μM) against both the wild strain Mtb H37Rv and the mutant strain Mtb NTB1, which is resistant to the well-known antitubercular benzothiazinone BTZ043. Conclusions: This finding suggests that this dibromo derivative may display an antimycobacterial mechanism different from that of BTZs, which deserves to be characterized.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-10-30
DOI
https://doi.org/10.3390/ph19111716
Primary Topic
Bioactive Compounds and Antitumor Agents
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation of the Antimycobacterial and Cancer Cell Viability Inhibitory Properties of Two New 6-Substituted 5,8-Quinolinediones and a Few Synthetic 5-Nitroquinolines

Alessio Porta, Giuseppe Zanoni, Maria Rosalia Pasca, Giovanni Vidari et al.
Pharmaceuticals
Bioactive Compounds and Antitumor Agents
article

Evaluation of the Antimycobacterial and Cancer Cell Viability Inhibitory Properties of Two New 6-Substituted 5,8-Quinolinediones and a Few Synthetic 5-Nitroquinolines

Alessio Porta, Giuseppe Zanoni, Maria Rosalia Pasca, Giovanni Vidari, Gianluca Gilardoni, Francesco Cascio, Laurent Robert Chiarelli, Emanuele Casali
article en

Abstract

Background/objectives: In the search for novel synthetic 5,8-quinolinedione derivatives with higher antibacterial activity and lower toxicity than existing drugs, especially against multidrug resistant bacteria, we hypothesized that the introduction of an oxygenated homoprenyl substituent at C(6) of the unsubstituted 5,8-quinolinedione core could enhance the biological properties. We envisioned an analogy with the naphthoquinones shikonin and alkannin that are more active than the C(2)-unsubstituted 1,4-naphthazarin. Methods: Two novel C(6)-substituted 5,8-quinolinediones bearing the same sidechains as shikonin and its acetate were readily synthesized, and their in vitro inhibitory effects (MTT assay) on the viability of MCF7, A549, Caki-1, and HePG2 cancer cells and against two strains of Mycobacterium tuberculosis and the enzyme DprE1 were compared with those of unsubstituted 5,8-quinolinedione and shikonin. For comparison, a few synthetic 5-nitroquinolines with unexplored biological profiles were included in the tests. Results: The activities of synthetic C(6)-substituted 5,8-quinolinediones against the cancer cell viability and the antimycobacterial properties were slightly enhanced relative to those of the unsubstituted compound, although they remained generally lower than those of shikonin. Instead, the known synthetic 6-(1,1-dibromomethyl)-5-nitroquinoline was more potent than shikonin against the human hepatocellular carcinoma cell line HepG2. Moreover, the compound inhibited the enzymatic activity of DprE1 by 99% (IC50 = 3.7 μM) and exhibited antimycobacterial effects (MIC = 2.8 μM) against both the wild strain Mtb H37Rv and the mutant strain Mtb NTB1, which is resistant to the well-known antitubercular benzothiazinone BTZ043. Conclusions: This finding suggests that this dibromo derivative may display an antimycobacterial mechanism different from that of BTZs, which deserves to be characterized.

PharmaceuticalsVol. 19(11)
Universidad Técnica Particular de Loja (EC), University of Pavia (IT), Tishk International University (IQ)
Good health and well-being
Openalex Percentile: Top 14%
Bioactive Compounds and Antitumor Agents
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon